J 113863
Latest Information Update: 15 Dec 2003
Price :
$50 *
At a glance
- Originator Banyu
- Class Anti-inflammatories
- Mechanism of Action CCR1 receptor antagonists; CCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 15 Dec 2003 No development reported - Preclinical for Multiple sclerosis in Japan (unspecified route)
- 15 Dec 2003 No development reported - Preclinical for Rheumatoid arthritis in Japan (unspecified route)
- 10 May 2001 Preclinical development for Multiple sclerosis in Japan (Unknown route)